Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
13F holders, Q2 2024
Institutional positions in Belite Bio, Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- 0 vs. Q1 2024
- Shares held
- 186.6K
- +128.5K (+221.0%) vs. Q1 2024
- Total value
- $8.52M
- +$6.29M (+282.2%) vs. Q1 2024
- New holders
- 2
- 2 more added
- Sold out
- 2
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLTE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 80 | $1.44B |
| Q1 2026 | 75 | $1.42B |
| Q4 2025 | 69 | $1.15B |
| Q3 2025 | 34 | $169.3M |
| Q2 2025 | 18 | $4.51M |
| Q1 2025 | 18 | $9.91M |
| Q4 2024 | 22 | $17.8M |
| Q3 2024 | 15 | $3.69M |
| Q2 2024 | 11 | $8.52M |
| Q1 2024 | 11 | $2.23M |
| Q4 2023 | 17 | $7.10M |
| Q3 2023 | 7 | $3.17M |
| Q2 2023 | 6 | $14.9M |
| Q1 2023 | 8 | $25.4M |
| Q4 2022 | 7 | $25.9M |
| Q3 2022 | 8 | $3.87M |
| Q2 2022 | 6 | $2.15M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Belite Bio, Inc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 148,000 | $6.76M | 0.18% | +148,000 | New |
| State Street Corp | 15,671 | $715.9K | 0.00% | −999−6.0% | Reduced |
| Point72 Asset Management, L.P. | 7,311 | $334.0K | 0.00% | −1,389−16.0% | Reduced |
| Geode Capital Management, LLC | 6,700 | $306.1K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 5,409 | $247.0K | 0.00% | +5,409 | New |
| Virtus ETF Advisers LLC | 1,807 | $82.5K | 0.04% | −152−7.8% | Reduced |
| Morgan Stanley | 1,044 | $47.7K | 0.00% | −5,046−82.9% | Reduced |
| GAMMA Investing LLC | 428 | $19.6K | 0.00% | +194+82.9% | Added |
| Bank of America Corp | 102 | $4.66K | 0.00% | −1,622−94.1% | Reduced |
| JPMorgan Chase & Co | 88 | $4.02K | 0.00% | −570−86.6% | Reduced |
| Advisor Group Holdings, Inc. | 8 | $365 | 0.00% | +3+60.0% | Added |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −10,584−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −4,788−100.0% | Sold out |